Page 720 of 1,034: studies 7,191 to 7,200 of 10,336, newest first. Back to the depression overview
Psychedelics as Psychiatric Medications March 1, 2023 Michael C Mithoefer, David E. Presti
Abstract MDMA (3,4-methylenedioxymethamphetamine) was originally synthesized and patented by the Merck chemical company in 1914. It was not explored for human use until the 1970–80s when there were published reports that it could be a useful catalyst to psychotherapy, in part because it often produced reduced anxiety and increased emotional openness. In 1985, in response to media attention to...
Psychedelics as Psychiatric Medications March 1, 2023 Daniel Perkins, Simon Ruffell, Jerome Sarris
Abstract Ayahuasca is a psychedelic plant brew originating in the Amazon basin. It is typically made from two basic components: the ayahuasca vine (Banisteriopsis caapi), containing various harmala alkaloids, and the leaves of a plant containing the potent psychedelic dimethyltryptamine (DMT), such as the chacruna plant (Psychotria viridis). Evidence suggests the brew has been used for at least...
European Psychiatry March 1, 2023 V. W. L. Tsang, Brendan Tao, Shannon Dames et al. 1 citation
IntroductionKetamine has been increasingly used to treat mental health conditions yet there is a lack of safety data on intramuscular (IM) and sublingual (SL) dosing in a community setting. The Roots to Thrive Ketamine assisted Therapy (RTT-KaT) program is a 12-week program with 12 Community of Practice (CoP) group therapy sessions and three ketamine sessions.ObjectivesTo provide preliminary...
Psychedelics as Psychiatric Medications March 1, 2023 Mihai Avram, Felix Müller, Stefan Borgwardt 1 citation
Abstract Lysergic acid diethylamide (LSD) is a potent perception-altering chemical. Since the discovery of its effects almost eighty years ago, LSD has been revered and demonized. Before its ban in the late 1960s, LSD was used to model aspects of psychosis and treat distinct mental disorders such as alcohol addiction and anxiety. The new wave of research on psychedelics as potential treatments...
PPmP - Psychotherapie · Psychosomatik · Medizinische Psychologie March 1, 2023 Anne Karow 1 citation
Psychedelische Substanzen haben sich über die letzten Jahre überraschend zu neuen Hoffnungsträgern für eine Verbesserung des Therapieerfolgs in der Behandlung verschiedener psychischer Erkrankungen entwickelt. Auslöser für die Renaissance psychedelischer Therapien waren nicht allein pharmakologische Innovationen der letzten Jahre, sondern auch eine steigende Ratlosigkeit angesichts...
European Psychiatry March 1, 2023 Saundarai Bhanot, Michelle Cq Lin, S. Bains et al. 3 citations
Introduction Psilocybin is a naturally occurring psychedelic compound whose effects have been seen in studies for treatment of depression, anxiety and pain management. Given its structural similarities to 5-hydroxytryptamine, a monoamine controlling brain modulation of pain input, preliminary studies sought to test serotonergic interactions of psilocybin with headaches. Objectives Explore...
March 1, 2023 David Nutt, David Castle 4 citations
Abstract There is substantial contemporary interest in psychedelic agents as medicines for maladies of the mind. This follows research in the 1950s and 1960s exploring the use of LSD and other psychedelics to treat a range of psychiatric illnesses as well as addictions. This research was shut down after prohibition of these drugs; however, the last decade has seen a major renewal of interest in...
Psychological Medicine March 1, 2023 Isabel Wießner, Marcelo Falchi, Fernanda Palhano-Fontes et al. 53 citations
For a century, psychedelics have been investigated as models of psychosis for demonstrating phenomenological similarities with psychotic experiences and as therapeutic models for treating depression, anxiety, and substance use disorders. This study sought to explore this paradoxical relationship connecting key parameters of the psychotic experience, psychotherapy, and psychedelic experience. In...
Frontiers in Psychiatry March 1, 2023 Karl Kristjan Kaup, Madis Vasser, Kadi Tulver et al. 22 citations
Background: Recent research has shown promising results for the therapeutic benefits of psychedelics. One popular view claims that these benefits are mediated by the subjective experiences induced by these substances. Based on this, we designed a virtual reality experience, Psyrreal, that mimics the phenomenological components of psychedelic experiences. Aims: We aimed to investigate the...
Psychedelic Medicine March 1, 2023 Lucas Dwiel, Angela Henricks, Elise Bragg et al. 4 citations
Psychedelic drugs have resurged in neuroscience and psychiatry with promising success in psychedelic-assisted therapy for the treatment of anxiety, depression, and addiction. At the cellular level, psychedelic drugs elicit neuroplastic processes 24 h after administration, priming neural circuits for change. The acute effects of psychedelic drugs are well characterized with functional imaging...